MARKET

IPHYF

IPHYF

Innate Pharma Marseille
OTCPK
2.250
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
2.250
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.250
52 WEEK LOW
1.580
MARKET CAP
210.83M
P/E (TTM)
-3.4927
1D
5D
1M
3M
1Y
5Y
1D
Innate Pharma to Court Investors at Jefferies Global Healthcare Conference 2026
TipRanks · 1d ago
H.C. Wainwright Sticks to Their Buy Rating for Innate Pharma (IPHA)
TipRanks · 6d ago
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
TipRanks · 6d ago
Innate Pharma Posts Q1 2026 Results as Key Oncology Trials Advance and Cash Runway Tightens
TipRanks · 05/13 12:42
Innate Pharma Updates Share Capital and Voting Rights as of April 16, 2026
TipRanks · 05/12 10:30
Innate Pharma Schedules May 13 Webcast on First-Quarter 2026 Business Progress
TipRanks · 05/06 10:58
Innate Pharma Plans Investor Meetings at D. Boral Capital Global Conference in New York
TipRanks · 04/23 10:30
Innate Pharma Showcases Encouraging Phase 2 IPH5201 Lung Cancer Data at AACR 2026
TipRanks · 04/17 19:28
More
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Webull offers Innate Pharma SA stock information, including OTCPK: IPHYF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHYF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPHYF stock methods without spending real money on the virtual paper trading platform.